DE602004028448D1 - Orale zubereitungen enthaltend cladribin - Google Patents

Orale zubereitungen enthaltend cladribin

Info

Publication number
DE602004028448D1
DE602004028448D1 DE602004028448T DE602004028448T DE602004028448D1 DE 602004028448 D1 DE602004028448 D1 DE 602004028448D1 DE 602004028448 T DE602004028448 T DE 602004028448T DE 602004028448 T DE602004028448 T DE 602004028448T DE 602004028448 D1 DE602004028448 D1 DE 602004028448D1
Authority
DE
Germany
Prior art keywords
cladribin
preparations containing
oral preparations
cladribine
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004028448T
Other languages
English (en)
Inventor
Nicholas S Bodor
Yogesh Dandiker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ares Trading SA
Original Assignee
Ares Trading SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading SA filed Critical Ares Trading SA
Publication of DE602004028448D1 publication Critical patent/DE602004028448D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE602004028448T 2003-03-28 2004-03-26 Orale zubereitungen enthaltend cladribin Expired - Lifetime DE602004028448D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45892203P 2003-03-28 2003-03-28
US48475603P 2003-07-02 2003-07-02
US54124704P 2004-02-04 2004-02-04
PCT/US2004/009387 WO2004087101A2 (en) 2003-03-28 2004-03-26 Oral formulations of cladribine

Publications (1)

Publication Number Publication Date
DE602004028448D1 true DE602004028448D1 (de) 2010-09-16

Family

ID=33135982

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004028448T Expired - Lifetime DE602004028448D1 (de) 2003-03-28 2004-03-26 Orale zubereitungen enthaltend cladribin

Country Status (28)

Country Link
US (2) US7888328B2 (de)
EP (1) EP1608344B1 (de)
JP (1) JP5256611B2 (de)
KR (1) KR101129816B1 (de)
AT (1) ATE476177T1 (de)
AU (2) AU2004226437B2 (de)
BR (2) BR122018068797B1 (de)
CA (1) CA2520523C (de)
CY (2) CY1112591T1 (de)
DE (1) DE602004028448D1 (de)
DK (2) DK1608344T3 (de)
EA (1) EA009944B1 (de)
ES (1) ES2409884T3 (de)
HK (2) HK1089654A1 (de)
HR (1) HRP20050925A2 (de)
HU (1) HUS1800013I1 (de)
IL (1) IL213853A0 (de)
IS (1) IS2799B (de)
LT (1) LTC1608344I2 (de)
LU (1) LUC00065I2 (de)
ME (1) ME00249B (de)
MX (1) MXPA05010329A (de)
NO (1) NO20054945L (de)
PL (1) PL1608344T3 (de)
PT (1) PT1608344E (de)
RS (2) RS20050735A (de)
SG (1) SG175450A1 (de)
WO (1) WO2004087101A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05010330A (es) * 2003-03-28 2006-05-31 Ivax Corp Formulaciones de cladribina para el mejor suministro oral y a traves de la mucosa.
ES2921858T3 (es) 2004-12-22 2022-09-01 Merck Serono Sa Régimen de cladribina en el tratamiento de la esclerosis múltiple
EA020805B1 (ru) * 2006-05-24 2015-01-30 Мерк Сероно С.А. Применение комбинации кладрибина и бета-интерферона для лечения рассеянного склероза
EP2343074A1 (de) 2009-12-23 2011-07-13 Merck Serono S.A. Verwendung von Purinanaloga zur Behandlung von Atemwegserkrankungen
EP2428201A1 (de) 2010-09-08 2012-03-14 Merck Serono S.A. Orale Verabreichung von Nukleosidmonophosphaten
WO2012097867A1 (en) 2011-01-18 2012-07-26 Synthon Bv Cladribine particles and pharmaceutical compositions comprising them
JP2021504363A (ja) 2017-11-24 2021-02-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 進行型多発性硬化症の処置における使用のためのクラドリビン処方計画
EP3628310A1 (de) 2018-09-25 2020-04-01 Synbias Pharma AG Pharmazeutische zusammensetzung mit festen dispersionen von amorphem cladribin und pharmazeutisch akzeptabler wasserlöslicher träger
RU2748311C1 (ru) * 2020-01-29 2021-05-21 Общество с ограниченной ответственностью "ФармЭко" Фармацевтическая композиция, содержащая твердые дисперсии аморфного кладрибина и фармацевтически приемлемый водорастворимый носитель
WO2022053608A1 (en) 2020-09-10 2022-03-17 Merck Patent Gmbh Novel treatment regimen for the treatment of autoimmune disorders
JP2024508151A (ja) 2021-03-03 2024-02-22 アレス トレーディング ソシエテ アノニム 自己免疫疾患治療のためのｄｍｄを使用する改善された治療法、並びに該治療法を予測及び／又は最適化するためのバイオマーカー
RU2758436C1 (ru) * 2021-04-05 2021-10-28 Общество с ограниченной ответственностью «ФармЭко» Способ получения аморфных ко-эвапоратов кладрибина с циклодекстринами
WO2022229761A1 (en) * 2021-04-28 2022-11-03 Biophore India Pharmaceuticals Pvt Ltd SOLID FORM OF 2-CHLORO-2'-DEOXY-ADENOSINE COMPLEX WITH HPβCD
WO2023242285A1 (en) 2022-06-15 2023-12-21 Vektor Pharma Tf Gmbh Sublingual formulation of anticancer compound for use in the treatment of autoimmune neurodegenerative diseases

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
HU181703B (en) 1980-05-09 1983-11-28 Chinoin Gyogyszer Es Vegyeszet Process for producing aqueus solutuins of water insoluble or hardly soluble vitamines, steroides, localanesthetics, prostanoides and non-steroid and antiphlogistic agents
JPS5838250A (ja) * 1981-09-01 1983-03-05 Teikoku Chem Ind Corp Ltd 複合体
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
JPS58177949A (ja) * 1982-04-12 1983-10-18 Takeda Chem Ind Ltd ランカシジン群抗生物質包接化合物
EP0094157B1 (de) 1982-04-30 1987-07-29 Takeda Chemical Industries, Ltd. Pharmazeutische Zusammensetzung und ihre Verwendung
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
DE3317064A1 (de) 1983-05-10 1984-11-15 Consortium für elektrochemische Industrie GmbH, 8000 München Verfahren zur herstellung von cyclooctaamylose
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US4870060A (en) * 1985-03-15 1989-09-26 Janssen Pharmaceutica Derivatives of γ-cylodextrin
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5106837A (en) * 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4920214A (en) 1986-04-16 1990-04-24 American Maize-Products Company Process for producing modified cyclodextrins
JPS62281855A (ja) * 1986-05-29 1987-12-07 Daikin Ind Ltd ビタミン，ビタミン誘導体，またはホルモンを含有する包接化合物
JP2575460B2 (ja) * 1988-05-12 1997-01-22 東京田辺製薬株式会社 ダナゾール−シクロデキストリン包接化合物
DK0465535T3 (da) 1989-04-03 1999-03-01 Janssen Pharmaceutica Nv Regioselektive substitutioner i cyclodextriner
JPH035438A (ja) * 1989-05-31 1991-01-11 Kaken Pharmaceut Co Ltd フルルビプロフェン包接化合物およびこの包接化合物を用いる消炎鎮痛剤
AU678557B2 (en) * 1992-05-19 1997-06-05 Scripps Research Institute, The Use of 2-halo adenine derivatives as therapeutic agents against chronic myelogenous leukemia
DE4237639A1 (de) * 1992-11-07 1994-05-11 Basf Ag Verfahren zur Herstellung von Polymeren mit NLO-aktiven Seitengruppen und deren Verwendung
US5424296A (en) * 1993-04-15 1995-06-13 The Scripps Research Institute 2-Halo-2'-deoxyadenosines as therapeutic agents against malignant astrocytoma
US5510336A (en) * 1994-09-06 1996-04-23 Saven; Alan 2-halo-2'-deoxyadenosine treatment for histiocytosis
BR9611562A (pt) * 1995-11-23 1999-03-02 Janssen Pharmaceutica Nv Misturas sólidas de ciclodextrinas preparadas via extrusão sob fusão
JPH10265495A (ja) * 1997-03-25 1998-10-06 Meiji Milk Prod Co Ltd フルオロプロゲステロン誘導体包接化合物
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6699849B1 (en) * 1998-02-23 2004-03-02 Cyclops, Ehf. Cyclodextrin complexes of benzodiazepines
NZ505951A (en) 1998-02-23 2003-02-28 Cyclops Ehf A method for enhancing the complexation efficiency of a heterocyclic drug with cyclodextrin, by subjecting the heterocycloc drug to chemically reversible ring-opening
AU3954799A (en) 1998-05-29 1999-12-20 Janssen Pharmaceutica N.V. Acylated alkylated cyclodextrin derivatives and their use as carriers for medicaments
US6174873B1 (en) * 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
US6194395B1 (en) * 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
US6239118B1 (en) * 1999-10-05 2001-05-29 Richard A. Schatz Method for preventing restenosis using a substituted adenine derivative
US7141555B2 (en) * 2000-12-19 2006-11-28 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures

Also Published As

Publication number Publication date
HK1150266A1 (en) 2011-11-18
KR20060015487A (ko) 2006-02-17
US7888328B2 (en) 2011-02-15
BRPI0408848B1 (pt) 2018-11-27
WO2004087101A2 (en) 2004-10-14
LUC00065I2 (de) 2018-03-28
HK1089654A1 (en) 2006-12-08
KR101129816B1 (ko) 2012-03-26
IL213853A0 (en) 2011-07-31
HUS1800013I1 (hu) 2018-03-28
PL1608344T3 (pl) 2011-01-31
US20070197468A1 (en) 2007-08-23
EP1608344A2 (de) 2005-12-28
BRPI0408848A8 (pt) 2017-12-26
AU2010214777A1 (en) 2010-09-23
ATE476177T1 (de) 2010-08-15
CA2520523C (en) 2011-10-11
AU2010214777B2 (en) 2013-01-31
RS20050735A (en) 2008-06-05
EA009944B1 (ru) 2008-04-28
AU2004226437A1 (en) 2004-10-14
NO20054945L (no) 2005-11-24
CY2018005I1 (el) 2018-06-27
LTPA2018502I1 (lt) 2018-03-12
ME00249B (me) 2011-05-10
BR122018068797B1 (pt) 2021-04-27
IS2799B (is) 2012-09-15
RS51115B (sr) 2010-10-31
MXPA05010329A (es) 2006-05-31
MEP34308A (en) 2011-02-10
US20110097306A1 (en) 2011-04-28
EA200600404A1 (ru) 2006-08-25
DK2272503T3 (da) 2013-05-21
ES2409884T3 (es) 2013-06-28
WO2004087101A3 (en) 2005-02-03
US8785415B2 (en) 2014-07-22
NO20054945D0 (no) 2005-10-25
PT1608344E (pt) 2010-09-02
JP2006521403A (ja) 2006-09-21
HRP20050925A2 (en) 2006-08-31
BRPI0408848B8 (pt) 2021-07-27
CY1112591T1 (el) 2016-02-10
EP1608344B1 (de) 2010-08-04
BRPI0408848A (pt) 2006-04-04
RS20050734A (en) 2008-06-05
LTC1608344I2 (lt) 2019-03-12
CA2520523A1 (en) 2004-10-14
CY2018005I2 (el) 2018-06-27
JP5256611B2 (ja) 2013-08-07
AU2004226437B2 (en) 2010-06-03
SG175450A1 (en) 2011-11-28
IS8051A (is) 2005-09-28
DK1608344T3 (da) 2010-09-06
LUC00065I1 (de) 2018-02-14

Similar Documents

Publication Publication Date Title
LTC1608344I2 (lt) Per burną vartojamos kladribino kompozicijos
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
NO20054944L (no) Cladribinformuleringer for forbedret oral og transmuskos administrering
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
SE0102315D0 (sv) Compounds
DE60334773D1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
SE0301700D0 (sv) Novel compounds
GT200800107A (es) Formulaciones orales que comprenden tigeciclina
NO20063293L (no) Farmasoytiske forbindelser
IL173809A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
RS20050649A (en) Antibacterial indolone oxazolidinones,intermediates for their preparation and pharmaceutical compositions containing them
ITMI20031714A1 (it) Formazioni ad azione antitumorale.
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение
DE602004008051D1 (de) Aus einer bifidobakterien-kultur gewonnener immunomodulator und diesen enthaltende zusammensetzungen
NO20085285L (no) 2-alkosy-3,4,5-tnhydroksyalkylamidbenzazepiner, deres fremstilling og bruk samt preparater inneholdende disse
EP2272503A3 (de) Orale Zubereitungen enthaltend Cladribin
UY27363A1 (es) Compuestos